Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 12/2016

30.09.2016 | Original Article

Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2

verfasst von: Wei Wang, Amy K. Erbe, Mikayla Gallenberger, KyungMann Kim, Lakeesha Carmichael, Dustin Hess, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Su-Chun Cheng, Sabina Signoretti, Michael Atkins, Alexander Carlson, Jonathan M. Weiss, James Mier, David Panka, David F. McDermott, Paul M. Sondel

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

NK cells play a role in many cancer immunotherapies. NK cell activity is tightly regulated by killer immunoglobulin-like receptor (KIR) and KIR–ligand interactions. Inhibitory KIR–ligands have been identified as HLA molecules, while activating KIR–ligands are largely unknown. Individuals that have not inherited the corresponding KIR–ligand for at least one inhibitory KIR gene are termed the “KIR–ligand missing” genotype, and they are thought to have a subset of NK cells that express inhibitory KIRs for which the corresponding KIR–ligand is missing on autologous tissue, and thus will not be inhibited through KIR–ligand recognition. In some settings where an anticancer immunotherapeutic effect is likely mediated by NK cells, individuals with a KIR–ligand missing genotype have shown improved clinical outcome compared to individuals with an “all KIR–ligands present” genotype. In addition, patients receiving hematopoietic stem cell transplants for leukemia may do better if their donor has more activating KIR genes (i.e., KIR haplotype-B). In a recent multi-institution clinical trial of patients with metastatic renal cell carcinoma receiving high-dose IL2 (HD-IL2), 25 % of patients showed a complete or partial tumor response to this therapy. We genotyped KIR and KIR–ligand genes for these patients (n = 107) and tested whether KIR/KIR–ligand genotypes correlated with patient clinical outcomes. In these analyses, we did not find any significant association of KIR/KIR–ligand genotype (either KIR–ligand missing or the presence of KIR haplotype-B) with patient outcome in response to the HD-IL2 therapy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncol (Williston Park) 23(6):488–496 Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncol (Williston Park) 23(6):488–496
2.
Zurück zum Zitat McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB (2015) The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 21(3):561–568. doi:10.1158/1078-0432.CCR-14-1520 CrossRefPubMed McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB (2015) The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 21(3):561–568. doi:10.​1158/​1078-0432.​CCR-14-1520 CrossRefPubMed
4.
Zurück zum Zitat Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM (2010) Genotypes of NK cell KIR receptors, their ligands, and Fc receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70(23):9554–9561. doi:10.1158/0008-5472.can-10-2211 CrossRefPubMedPubMedCentral Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM (2010) Genotypes of NK cell KIR receptors, their ligands, and Fc receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70(23):9554–9561. doi:10.​1158/​0008-5472.​can-10-2211 CrossRefPubMedPubMedCentral
5.
6.
Zurück zum Zitat Tarek N, Luduec JL, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NV, Hsu KC (2012) Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Investig 122(9):3260–3270. doi:10.1172/jci62749 CrossRefPubMedPubMedCentral Tarek N, Luduec JL, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NV, Hsu KC (2012) Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Investig 122(9):3260–3270. doi:10.​1172/​jci62749 CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O’Reilly RJ, Cheung NKV, Hsu KC (2009) KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 15(23):7330–7334. doi:10.1158/1078-0432.ccr-09-1720 CrossRefPubMedPubMedCentral Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O’Reilly RJ, Cheung NKV, Hsu KC (2009) KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 15(23):7330–7334. doi:10.​1158/​1078-0432.​ccr-09-1720 CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SGE, Guethlein LA, Parham P, Miller JS, Weisdorf DJ (2008) Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113(3):726–732. doi:10.1182/blood-2008-07-171926 CrossRefPubMed Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SGE, Guethlein LA, Parham P, Miller JS, Weisdorf DJ (2008) Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113(3):726–732. doi:10.​1182/​blood-2008-07-171926 CrossRefPubMed
10.
Zurück zum Zitat Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SGE, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116(14):2411–2419. doi:10.1182/blood-2010-05-283051 CrossRefPubMedPubMedCentral Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SGE, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116(14):2411–2419. doi:10.​1182/​blood-2010-05-283051 CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Marsh SGE, Spellman S, Haagenson MD, Saeturn K, Ladner M, Trachtenberg E, Parham P, Miller JS (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192(10):4592–4600. doi:10.4049/jimmunol.1302517 CrossRefPubMedPubMedCentral Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Marsh SGE, Spellman S, Haagenson MD, Saeturn K, Ladner M, Trachtenberg E, Parham P, Miller JS (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192(10):4592–4600. doi:10.​4049/​jimmunol.​1302517 CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B (2007) KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 179(2):854–868CrossRefPubMed Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B (2007) KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 179(2):854–868CrossRefPubMed
14.
Zurück zum Zitat Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P (2008) Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 180(6):3969–3979CrossRefPubMed Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P (2008) Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 180(6):3969–3979CrossRefPubMed
15.
Zurück zum Zitat Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL (1994) NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 180(2):537–543CrossRefPubMed Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL (1994) NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 180(2):537–543CrossRefPubMed
16.
Zurück zum Zitat Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100. doi:10.1126/science.1068440 CrossRefPubMed Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100. doi:10.​1126/​science.​1068440 CrossRefPubMed
17.
Zurück zum Zitat Pérez-Martínez A, Leung W, Muñoz E, Iyengar R, Ramírez M, Vicario JL, Lassaletta Á, Sevilla J, González-Vicent M, Madero L, Díaz-Pérez MÁ (2009) KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer 53(1):120–124. doi:10.1002/pbc.21955 CrossRefPubMed Pérez-Martínez A, Leung W, Muñoz E, Iyengar R, Ramírez M, Vicario JL, Lassaletta Á, Sevilla J, González-Vicent M, Madero L, Díaz-Pérez MÁ (2009) KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer 53(1):120–124. doi:10.​1002/​pbc.​21955 CrossRefPubMed
18.
Zurück zum Zitat Linn YC, Phang CY, Lim TJ, Chong SF, Heng KK, Lee JJ, Loh Y, Hwang W, Goh YT, Koh M (2010) Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients. Bone Marrow Transplant 45(6):1031–1037. doi:10.1038/bmt.2009.303 CrossRefPubMed Linn YC, Phang CY, Lim TJ, Chong SF, Heng KK, Lee JJ, Loh Y, Hwang W, Goh YT, Koh M (2010) Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients. Bone Marrow Transplant 45(6):1031–1037. doi:10.​1038/​bmt.​2009.​303 CrossRefPubMed
19.
Zurück zum Zitat Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM (1990) Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50(17):5234–5239PubMed Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM (1990) Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50(17):5234–5239PubMed
20.
Zurück zum Zitat Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, Reisfeld R, Seeger RC, Reynolds CP, Bauer M et al (1994) Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphasis Tumor Immunol 15(1):29–37CrossRefPubMed Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, Reisfeld R, Seeger RC, Reynolds CP, Bauer M et al (1994) Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphasis Tumor Immunol 15(1):29–37CrossRefPubMed
21.
Zurück zum Zitat Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, Heller G, Cheung NK, Hsu KC (2016) KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma. J Clin Oncol 34(21):2443–2451. doi:10.1200/JCO.2015.64.9558 CrossRefPubMed Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, Heller G, Cheung NK, Hsu KC (2016) KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma. J Clin Oncol 34(21):2443–2451. doi:10.​1200/​JCO.​2015.​64.​9558 CrossRefPubMed
23.
Zurück zum Zitat Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. doi:10.1016/j.jbi.2008.08.010 CrossRefPubMed Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. doi:10.​1016/​j.​jbi.​2008.​08.​010 CrossRefPubMed
24.
Zurück zum Zitat Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 39(Database issue):D913–D919. doi:10.1093/nar/gkq1128 CrossRefPubMed Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 39(Database issue):D913–D919. doi:10.​1093/​nar/​gkq1128 CrossRefPubMed
26.
27.
Zurück zum Zitat Maxwell W, McDevitt J, Reid I, Sharpe I, Feighery C, Tanner WA, Emmons R, Monson JR (1993) Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma. Eur J Surg Oncol 19(3):265–272PubMed Maxwell W, McDevitt J, Reid I, Sharpe I, Feighery C, Tanner WA, Emmons R, Monson JR (1993) Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma. Eur J Surg Oncol 19(3):265–272PubMed
28.
Zurück zum Zitat Thompson JA, Lee DJ, Cox WW, Lindgren CG, Collins C, Neraas KA, Dennin RA, Fefer A (1987) Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 47(15):4202–4207PubMed Thompson JA, Lee DJ, Cox WW, Lindgren CG, Collins C, Neraas KA, Dennin RA, Fefer A (1987) Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 47(15):4202–4207PubMed
29.
Zurück zum Zitat Becker S, Tonn T, Füssel T, Uhrberg M, Bogdanow M, Seifried E, Seidl C (2003) Assessment of killer cell immunoglobulinlike receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands. Hum Immunol 64(2):183–193. doi:10.1016/s0198-8859(02)00802-9 CrossRefPubMed Becker S, Tonn T, Füssel T, Uhrberg M, Bogdanow M, Seifried E, Seidl C (2003) Assessment of killer cell immunoglobulinlike receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands. Hum Immunol 64(2):183–193. doi:10.​1016/​s0198-8859(02)00802-9 CrossRefPubMed
30.
Zurück zum Zitat Kehrl JH, Dukovich M, Whalen G, Katz P, Fauci AS, Greene WC (1988) Novel interleukin-2 (Il-2) receptor appears to mediate Il-2-induced activation of natural-killer cells. J Clin Investig 81(1):200–205. doi:10.1172/Jci113295 CrossRefPubMed Kehrl JH, Dukovich M, Whalen G, Katz P, Fauci AS, Greene WC (1988) Novel interleukin-2 (Il-2) receptor appears to mediate Il-2-induced activation of natural-killer cells. J Clin Investig 81(1):200–205. doi:10.​1172/​Jci113295 CrossRefPubMed
31.
Zurück zum Zitat Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang JY, Yu JH, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13):2286–2294. doi:10.1182/blood-2010-02-271874 CrossRefPubMedPubMedCentral Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang JY, Yu JH, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13):2286–2294. doi:10.​1182/​blood-2010-02-271874 CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat MacFarlane AW, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS (2014) PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2(4):320–331. doi:10.1158/2326-6066.CIR-13-0133 CrossRefPubMed MacFarlane AW, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS (2014) PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2(4):320–331. doi:10.​1158/​2326-6066.​CIR-13-0133 CrossRefPubMed
33.
34.
Zurück zum Zitat Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ (2016) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. doi:10.1136/gutjnl-2015-310839 Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ (2016) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. doi:10.​1136/​gutjnl-2015-310839
36.
Zurück zum Zitat Scquizzato E, Zambello R, Teramo A, Baesso I, Varotto S, Albergoni MP, Boscaro E, Cesaro S, Pillon M, Calore E, Gazzola MV, Semenzato G, Messina C, Trentin L (2011) KIR/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation. Pediatr Transplant 15(2):198–204. doi:10.1111/j.1399-3046.2010.01447.x CrossRefPubMed Scquizzato E, Zambello R, Teramo A, Baesso I, Varotto S, Albergoni MP, Boscaro E, Cesaro S, Pillon M, Calore E, Gazzola MV, Semenzato G, Messina C, Trentin L (2011) KIR/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation. Pediatr Transplant 15(2):198–204. doi:10.​1111/​j.​1399-3046.​2010.​01447.​x CrossRefPubMed
37.
Zurück zum Zitat Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR, Vlahiotis A, Piccirillo JF, Cella M, Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM (2008) HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA 105(8):3053–3058. doi:10.1073/pnas.0712229105 CrossRefPubMedPubMedCentral Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR, Vlahiotis A, Piccirillo JF, Cella M, Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM (2008) HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA 105(8):3053–3058. doi:10.​1073/​pnas.​0712229105 CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC (2012) HLA-C–dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367(9):805–816. doi:10.1056/NEJMoa1200503 CrossRefPubMedPubMedCentral Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC (2012) HLA-C–dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367(9):805–816. doi:10.​1056/​NEJMoa1200503 CrossRefPubMedPubMedCentral
Metadaten
Titel
Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2
verfasst von
Wei Wang
Amy K. Erbe
Mikayla Gallenberger
KyungMann Kim
Lakeesha Carmichael
Dustin Hess
Eneida A. Mendonca
Yiqiang Song
Jacquelyn A. Hank
Su-Chun Cheng
Sabina Signoretti
Michael Atkins
Alexander Carlson
Jonathan M. Weiss
James Mier
David Panka
David F. McDermott
Paul M. Sondel
Publikationsdatum
30.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 12/2016
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-016-1904-8

Weitere Artikel der Ausgabe 12/2016

Cancer Immunology, Immunotherapy 12/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.